Means and methods for the specific modulation of target genes in the CNS and the eye and methods for their identification
Provided are methods for the treatment of disorders of the central nervous system (CNS) and the eye. In particular, use of compositions comprising a compound capable of modulating a target gene or gene product is described for the preparation of a pharmaceutical composition for the treatment of disorders of the CNS and/or the eye, wherein the composition is designed to be administered outside the blood-CNS and the blood-retina barriers. Furthermore, methods are provided for identifying and obtaining nucleic acid molecules encoding polypeptides involved in CNS disorders or of the eye, methods for diagnosing said disorders as well as transgenic animal deficient in the expression of target genes identified in accordance with the described method. In addition, methods of identifying and isolating drugs that are particularly useful for the treatment of disorders related to the CNS and/or the eye are disclosed.
1. A method for the treatment of autosomal recessive retinitis pigmentosa or congenital stationary night blindness comprising:
administering to a subject a therapeutically effective amount of a composition comprising a dsRNA between 21 and 23 nucleotides in length and a carrier, said dsRNA having a nucleotide sequence corresponding to mRNA of a target gene expressed in the eye; said administering of the composition occurring outside the blood-retina barrier, said composition inhibiting the target gene by RNA interference inside the eye, thereby treating autosomal recessive retinitis pigmentosa or congenital stationary night blindness, and wherein said target gene is SEQ ID NO:1 or SEQ ID NO:3.
2. The method of claim 1 , wherein said autosomal recessive retinitis pigmentosa or congenital stationary night blindness is related to angiogenesis and/or neovascularization.
3. The method of claim 1 , wherein said autosomal recessive retinitis pigmentosa or congenital stationary night blindness is related to the retinal pigment epithelium (RPE), neurosensory retina, choroid, and a combination thereof.
4. The method of claim 1 , wherein the dsRNA comprises a terminal 3′-hydroxyl group.
5. The method of claim 1 , further comprising preparing the dsRNA.
6. The method of claim 1 , further comprising diagnosing a subject with autosomal recessive retinitis pigmentosa or congenital stationary night blindness or a predisposition to autosomal recessive retinitis pigmentosa or congenital stationary night blindness.
7. The method of claim 1 , further comprising isolating the target gene.
8. The method of claim 1 , wherein said administering is by systemic administration.